Tafasitamab Plus Lenalidomide Has Continued Efficacy and Safety in R/R DLBCL

The combination of tafasitamab and lenalidomide followed by tafasitamab maintenance prolonged responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Related Keywords

United Kingdom ,Hospira Incyte ,Nagesh Kalakonda ,Speaker Bureau ,University Of Liverpool ,International Prognostic Index ,Ann Arbor ,Tafasitamab And Lenalidomide Followed By Maintenance ,Patients With Relapsed Refractory Diffuse Largeb Cell Lymphoma ,L Mind Trial ,Nct02399085 ,Bbs ,Orcp ,Rcpath ,Phd ,The University Of Liverpool ,